Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Darunavir + cobicistat is a fixed-dose combination antiretroviral medication used in the treatment of human immunodeficiency virus (HIV) infection. It contains two active components: - Darunavir, an HIV protease inhibitor that works by inhibiting the viral protease enzyme, thereby preventing viral replication and reducing the amount of HIV in the blood. - Cobicistat, a pharmacokinetic enhancer (booster) that inhibits cytochrome P450 3A (CYP3A) enzymes. This increases plasma concentrations of darunavir by slowing its metabolism, allowing for more effective antiviral activity. The combination is indicated for use with other antiretroviral agents in adults and children weighing at least 40 kg. While it does not cure HIV or AIDS, it helps control viral load and supports immune function[1][2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on darunavir + cobicistat.